Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cancer
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:contraindication |
pregnancy
active infection |
| gptkbp:cost |
hundreds of thousands of US dollars
|
| gptkbp:countryOfOperation |
gptkb:China
gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:developedBy |
gptkb:Carl_June
gptkb:Michel_Sadelain |
| https://www.w3.org/2000/01/rdf-schema#label |
CAR-T Cell Therapy
|
| gptkbp:limitation |
high cost
limited efficacy in solid tumors complex manufacturing process |
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
gptkb:Novartis |
| gptkbp:mechanismOfAction |
redirects T cells to recognize and kill cancer cells
|
| gptkbp:monitors |
oncologist
|
| gptkbp:product |
gptkb:Tecartus
gptkb:Kymriah gptkb:Yescarta gptkb:Breyanzi |
| gptkbp:regulates |
BCMA antigen
CD19 antigen |
| gptkbp:relatedTo |
monoclonal antibodies
immune checkpoint inhibitors T-cell receptor therapy |
| gptkbp:requires |
leukapheresis
lymphodepleting chemotherapy genetic modification of T cells |
| gptkbp:researchInterest |
reducing toxicity
improving persistence of CAR-T cells expanding indications |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:standsFor |
Chimeric Antigen Receptor T-cell Therapy
|
| gptkbp:storage |
cryopreservation
|
| gptkbp:studiedBy |
solid tumors
|
| gptkbp:target |
cancer cells
|
| gptkbp:usedIn |
hematologic malignancies
|
| gptkbp:uses |
genetically engineered T cells
|
| gptkbp:bfsParent |
gptkb:Cell_Therapy
|
| gptkbp:bfsLayer |
6
|